Vaxcyte
The Associate Director, CMC Statistician will lead statistical efforts for vaccine specification setting and justification across late-stage development, regulatory submissions, and commercial lifecycle. This role collaborates with cross‑functional teams including Process Development, MSAT, Stability, Quality, Regulatory Affairs, and Manufacturing to develop data‑driven, patient‑centric approaches and author statistical sections of regulatory documents.
Headquarters
San Carlos, California, United States
Company Size
51-200 employees
Founded
2013
Vaxcyte is a clinical-stage vaccine innovation company dedicated to eliminating bacterial infections — including invasive pneumococcal disease, Group A Strep, and Shigella — using advanced chemistry and a proprietary cell-free protein synthesis platform. Its lead programs, VAX-31 (a 31-valent PCV) and VAX-24 (a 24-valent PCV), are being evaluated in Phase 3 trials for the prevention of invasive pneumococcal disease, with additional early-stage candidates targeting Group A Strep and Shigella. Vaxcyte is also investing up to $1 billion in U.S. biomanufacturing expansion to support scalable vaccine production.
Vaxcyte Shares Decline as Capital Research Global Investors Reduces Stake
6 hours ago
Latham & Watkins Advises on Vaxcyte’s US$550 Million Public Offering
1 month ago
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
6 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Vaxcyte.
18% below the average for this role
Vaxcyte Advances VAX 31 To Late Stage With Added Pipeline Potential
2 weeks ago